EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study

Masayoshi Harigai, Shinya Kaname, Naoto Tamura iD, Hiroaki Dobashi, Shinichi Kubono, Takumitsu Yoshida

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac037 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Masayoshi Harigai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatosis with Polyangiitis, Microscopic Polyangiitis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This subgroup analysis of the randomized, double-blind, Phase 3 ADVOCATE study evaluated the efficacy and safety of avacopan compared with tapered prednisone in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Methods

Patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) received either avacopan 30 mg twice daily for 52 weeks plus prednisone-matching placebo or tapered prednisone over 20 weeks plus avacopan-matching placebo for 52 weeks. The two primary efficacy endpoints were clinical remission at Week 26 and sustained remission at Week 52.

Results

Compared with the overall population (N = 330), Japanese patients (N = 21) were older and had worse renal function, and a higher proportion were female and had MPA. The proportion of Japanese patients with clinical remission at Week 26 was 9/11 (81.8%) with avacopan vs. 7/10 (70.0%) with prednisone (overall population: 72.3% vs. 70.1%) and with sustained remission at Week 52 was 8/11 (72.7%) vs. 4/10 (40.0%), respectively (overall population: 65.7% vs. 54.9%). The safety profile of avacopan was similar in Japanese patients and the overall study population.

Conclusions

The efficacy and safety of avacopan in Japanese patients with MPA or GPA were comparable to that observed in the overall ADVOCATE study population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatosis with PolyangiitisMicroscopic PolyangiitisFemaleHumansMaleAntibodies, Antineutrophil CytoplasmicEast Asian PeoplePrednisoneAniline CompoundsNipecotic Acids

Stichwörter der Autor:innen

ANCAJapanese patientsantineutrophil cytoplasmic antibody-associated vasculitisavacopansubgroup analysis

Substanzen

Antibodies, Antineutrophil CytoplasmicPrednisoneavacopanAniline CompoundsNipecotic Acids

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.
  • Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Medical Research Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Clinical Projects Management Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.

ORCID-Profile: Naoto Tamura

Zitieren

APA

Harigai, M., Kaname, S., Tamura, N., Dobashi, H., Kubono, S., & Yoshida, T. (2023). Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study. Modern Rheumatology. https://doi.org/10.1093/mr/roac037

Vancouver

Harigai M, Kaname S, Tamura N, Dobashi H, Kubono S, Yoshida T. Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study. Modern Rheumatology. 2023. doi:10.1093/mr/roac037

BibTeX
@article{Harigai2023,
  author = {Harigai, Masayoshi and Kaname, Shinya and Tamura, Naoto and Dobashi, Hiroaki and Kubono, Shinichi and Yoshida, Takumitsu},
  title = {Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac037}
}
Kostenlos starten →